Epithelial Ovarian Cancer Clinical Trials

34 recruiting

Epithelial Ovarian Cancer Trials at a Glance

38 actively recruiting trials for epithelial ovarian cancer are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Boston, New York, and Columbus. Lead sponsors running epithelial ovarian cancer studies include Case Comprehensive Cancer Center, Cukurova University, and Lei Li.

Browse epithelial ovarian cancer trials by phase

Treatments under study

About Epithelial Ovarian Cancer Clinical Trials

Looking for clinical trials for Epithelial Ovarian Cancer? There are currently 34 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epithelial Ovarian Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epithelial Ovarian Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 2

A Study of Isoquercetin in People With Ovarian Cancer

Ovarian CancerEpithelial Ovarian CancerSerous Ovarian Tumor
Memorial Sloan Kettering Cancer Center90 enrolled8 locationsNCT07303894
Recruiting
Phase 3

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.384 enrolled1 locationNCT06994195
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting
Phase 1

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian CancerRecurrentOvary Neoplasm+1 more
UNC Lineberger Comprehensive Cancer Center27 enrolled1 locationNCT06305299
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Solid TumorFallopian Tube CancerEpithelial Ovarian Cancer+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc172 enrolled24 locationsNCT04516447
Recruiting
Phase 1

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Ovarian CancerRecurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer
PhotonPharma, Inc.8 enrolled1 locationNCT06366490
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Not Applicable

Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)

Epithelial Ovarian Cancer
The First Hospital of Jilin University98 enrolled1 locationNCT07495397
Recruiting
Phase 1Phase 2

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

Ovarian CancerPancreatic AdenocarcinomaEpithelial Ovarian Cancer
Case Comprehensive Cancer Center22 enrolled1 locationNCT06412510
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07480954
Recruiting

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Epithelial Ovarian Cancer
Leiden University Medical Center300 enrolled1 locationNCT03862677
Recruiting
Not Applicable

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Epithelial Ovarian Cancer
Case Comprehensive Cancer Center20 enrolled1 locationNCT06386887
Recruiting
Phase 1

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Primary Peritoneal CarcinomaFallopian Tube CancerEpithelial Ovarian Cancer
Regeneron Pharmaceuticals90 enrolled5 locationsNCT06469281
Recruiting
Phase 3

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Epithelial Ovarian Cancer
AstraZeneca1,100 enrolled125 locationsNCT07218809
Recruiting
Phase 2

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Endometrioid Ovarian CancerFallopian Tube CancerEpithelial Ovarian Cancer+1 more
TORL Biotherapeutics, LLC230 enrolled66 locationsNCT06690775
Recruiting
Not Applicable

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Primary Peritoneal CarcinomaFallopian Tube CancerEpithelial Ovarian Cancer
Shanghai Gynecologic Oncology Group94 enrolled1 locationNCT05236686
Recruiting
Phase 1Phase 2

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Ovarian CarcinomaEpithelial Ovarian Cancer
Radboud University Medical Center10 enrolled1 locationNCT05773859
Recruiting
Not Applicable

Platino-resistance in Ovarian Cancer

Epithelial Ovarian Cancer
Institut Claudius Regaud600 enrolled1 locationNCT03954171